Linhaliq ()
- Region
- 🇪🇺 EU
- Company
- Aradigm Pharmaceuticals Limited
- Status
- Application withdrawn
- Therapeutic area
- Bronchiectasis
- Application
- EMEA/H/C/004394
- ATC
- J01MA02
- Official record
- www.ema.europa.eu
Indication
Treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa)
Regulatory milestones
No milestones recorded in the last year.
Follow Linhaliq
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.